Xeris Biopharma Files 8-K: Director Changes & Compensation
Ticker: XERS · Form: 8-K · Filed: Feb 24, 2025 · CIK: 1867096
| Field | Detail |
|---|---|
| Company | Xeris Biopharma Holdings, Inc. (XERS) |
| Form Type | 8-K |
| Filed Date | Feb 24, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, officer-changes, filing
TL;DR
Xeris Biopharma board shakeup and comp details filed. Watch for strategic shifts.
AI Summary
Xeris Biopharma Holdings, Inc. filed an 8-K on February 24, 2025, reporting on the departure of directors, election of new directors, and compensatory arrangements. The filing also includes Regulation FD disclosures and financial statements/exhibits.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy or governance, impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Changes in directorships and compensatory arrangements can indicate internal shifts that may affect future company performance and strategy.
Key Players & Entities
- Xeris Biopharma Holdings, Inc. (company) — Registrant
- February 24, 2025 (date) — Date of earliest event reported
FAQ
What specific director positions were affected by the departures?
The filing indicates the departure of directors but does not specify which positions were vacated in the provided text.
Were any new officers appointed?
The filing lists 'Appointment of Certain Officers' as an item, suggesting new appointments may have occurred, but details are not in the provided text.
What is the nature of the compensatory arrangements being disclosed?
The filing mentions 'Compensatory Arrangements of Certain Officers' but does not provide specific details on the nature of these arrangements in the provided text.
Are there any Regulation FD disclosures included in this filing?
Yes, 'Regulation FD Disclosure' is listed as an item in the filing.
What financial statements or exhibits are being filed with this 8-K?
The filing includes 'Financial Statements and Exhibits' as an item, but the specific contents are not detailed in the provided text.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on February 24, 2025 regarding Xeris Biopharma Holdings, Inc. (XERS).